Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis

NCT01826201 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: MOL4239
DRUG: Placebo

Sponsor

Moleculin, LLC